Clinical reviewer: Dr. Sarah Boss, MD

COGNIFUL publishes this guide and is part of THE BALANCE GROUP. Its residence is in Mallorca, Spain, not Switzerland. The Swiss service and overseas residence described below are different care models rather than equivalent luxury packages or an independent ranking. Eligibility and proposed treatment must be confirmed directly. [1] [2]

An assessment should identify prescribed medicines, nonprescribed drugs, alcohol, patterns of use, current symptoms, and previous care. It should consider what the person is trying to change and the practical support available. Drug treatment is selected according to the substances and individual circumstances, so a generic addiction package is not enough information for a decision. [3]

Include the medication’s original purpose and current prescriber when prescriptions are involved. Physical dependence on benzodiazepines can occur during prescribed use; assessment should not automatically equate that history with every addiction presentation. Abrupt changes can cause serious withdrawal and require a clinician-led plan. Do not alter medication simply to meet a prospective admission date. [4]

Acute breathing difficulty, seizures, severe chest pain, marked confusion, or an immediate psychiatric crisis require urgent medical care. The appropriate initial setting may be different from the place where later therapy occurs. Ask the clinician to establish readiness for any proposed travel and residence rather than allowing the booking process to determine the clinical sequence. [4] [5]

The Zurich service is not being presented as a luxury residence. It is a documented local specialist comparison, with an eligibility boundary that matters. Residents of other cantons should ask their clinician or relevant local service about access rather than assume a Zurich referral is available on the same terms. International private payment does not by itself establish access to every hospital service.

The comparison should ask what can be treated while living at home and what justifies time away. An outpatient pathway may fit someone who can attend reliably with suitable support. A residential stay may be considered when a more structured environment is appropriate. The recommendation should explain the clinical and practical reasons, rather than treat a residence as the default for a person seeking discretion. [3]

Opioid use disorder

Ask about medication treatment and continuity. The CDC recommends offering or arranging evidence-based medication for opioid use disorder and advises against detoxification alone without medication because of increased return-to-use and overdose risks. This clinical evidence should inform provider questions without being confused with a statement about Swiss or Spanish prescribing rules. [8]

PUK’s outpatient service explicitly describes opioid substitution treatment, while COGNIFUL’s general addiction information does not establish every opioid medication capability. Ask the actual receiving provider what it can deliver. If medication is already prescribed, coordinate with the current clinician before a change of country or setting. [6] [9]

Cocaine or another stimulant

Ask whether structured behavioral interventions are available. The ASAM/AAAP guideline identifies contingency management as a primary component of stimulant treatment alongside other psychosocial work. This is an organized method of reinforcing agreed treatment behaviors. Ask how it is delivered and how it relates to other approaches, rather than assuming a general therapy menu includes it. [5]

Also clarify how mood, anxiety, sleep, and other psychiatric symptoms are reviewed. The guideline recognizes that some needs can continue beyond the acute period. The plan should identify the clinician responsible and the conditions that would require another level of care. [5]

Prescription medication concerns

Ask the assessor to distinguish the original condition, physical dependence, and any problematic use. A medication review should not leave anxiety, sleep, pain, or another ongoing need without a treatment plan. If a change is proposed, establish who supervises it during the stay and who takes responsibility after returning to Switzerland. [4]

The expected residence length is not automatically the duration of a medical process. Ask how the program handles work that may continue beyond discharge. A responsible answer should not depend on accelerating medication changes to fit a purchased package.

Cannabis-related difficulties

Assess impaired control, craving, unsuccessful attempts to reduce use, and effects on responsibilities or relationships. The CDC describes these as relevant features of cannabis use disorder. Ask about psychological treatment options and whether the person’s circumstances support outpatient care. The need for a residential setting should be assessed separately from the fact that cannabis is involved. [10] [11]

When several concerns overlap

Ask how the team will coordinate the different parts of treatment. If addiction, medication, and mental health professionals are involved, identify who leads the overall plan and how disagreements are resolved. The patient should not be the only person passing information between separate appointments. A shared understanding of responsibilities matters whether care is delivered in one building or across several services.

Request a written sequence showing what needs to happen first, what can occur during residence, and what remains for follow-up. If a service is external, clarify who makes the referral and whether the receiving professional has agreed to participate. This prevents a proposed package from appearing complete when an essential clinical element is still unarranged.

Ask how progress will be reviewed with you. The goals should reflect the individual problem and may include treatment engagement, changes in use, medication continuity, functioning, or responses to difficult situations. A completed stay does not by itself explain what has improved or what support is still needed. Reviews should influence the next treatment decisions.

Finally, discuss what happens if the current setting cannot meet a new need. A clear escalation process is more useful than an assurance that a personalized program can handle every possibility. Ask who arranges additional assessment, how the patient is involved, and what information is transferred. These are practical questions about accountability, not reasons to assume that a complication is inevitable.

COGNIFUL is part of THE BALANCE GROUP and offers a private residential program in Mallorca. Its published addiction pathways name alcohol, cocaine, prescription drugs, and cannabis. Clinical suitability and availability are required for admission. The program should not be described as a Swiss facility or a universal service for every drug and acute presentation. Medical or psychiatric needs may require another setting first. [1] [9]

A maximum of four clients share the residence at any time, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, and personal manager are shared in both programs. Other holistic sessions, excursions, and activities are shared in Premier; every session and activity is individual in Premier Plus. Both tiers use this arrangement. The capacity describes the residential format; it does not establish a staffing ratio, clinical session count, or comparative outcome. [2]

COGNIFUL Premier and Premier Plus both include assessment, an individual plan, and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Further base-program follow-up is agreed individually. Typical stays are four to twelve weeks, reviewed personally. [12] [13] View program fees

Ask for a substance-specific proposal naming the relevant methods, professionals, and review arrangements. COGNIFUL uses THE BALANCE GROUP’s clinical team according to the individual plan; a directory entry is not a promise that every clinician will participate. External guideline recommendations are useful questions for the team, not proof that every intervention is available in every program. [14] [15]

COGNIFUL is self-pay and does not directly bill insurers. Obtain a current written total with duration assumptions, inclusions, and exclusions, rather than relying on an old currency quotation. Discuss Swiss follow-up and prescribing responsibilities before committing. Any included aftercare must be workable in the actual place of residence; it should not be read as unrestricted cross-border treatment. [12] [13] [16]

Identify a receiving Swiss clinician or service and ask whether it can review the plan and accept follow-up. With consent, agree which records move between professionals and when. This is particularly important if a medical stabilization service, residence, and outpatient team all have roles. A travel arrangement does not substitute for clinical acceptance at each stage. [16]

Confirm the language of assessment, psychotherapy, medication explanations, and written recommendations. If the Mallorca and Swiss teams use different languages, agree how essential information will be communicated. The patient should understand the plan without becoming responsible for translating complex medical instructions between services.

Discuss practical responsibilities during the stay. The proposed clinical schedule should help you decide what work or family commitments need to be delegated. If relatives participate, define the purpose and consent boundaries. Their support should not replace a professional’s responsibility for medication, monitoring, or reassessment.

Before discharge, rehearse the return to ordinary routines. Which appointments are confirmed? What happens if symptoms worsen or substance use recurs? Who reviews medication? What support is available after a difficult day? The treatment team should help turn general recommendations into a plan that the person can actually use.

Compare complete costs and clinical content. If one provider recommends a different duration or intensity, ask which needs explain the difference. Clarify how external care is arranged and billed without assuming everything is included. The best choice is a transparent, suitable pathway, not simply the most expensive available residence.

Is a Zurich service automatically available to all Swiss residents?

No. Confirm eligibility. The PUK description identifies adults aged 18–65 and preferably canton of Zurich residents. People elsewhere should ask about the appropriate local or referral pathway. [7]

Does COGNIFUL provide every form of drug detox?

This guide does not establish that capability. Admission requires assessment, and withdrawal or acute medical and psychiatric needs may require care elsewhere first. Ask about the specific substances and symptoms involved. [9]

Should ongoing medication be stopped for a residential stay?

Do not make that decision from a program description. Coordinate with the prescriber and receiving clinicians. Benzodiazepine changes can carry serious withdrawal risks, and opioid medication continuity can be central to appropriate care. [4] [8]

What is the next step with COGNIFUL?

Request a suitability review, a written clinical and fee proposal, and a Swiss continuing-care discussion. Share accurate substance and medication information and involve existing clinicians with consent where useful. Confirm necessary prior care before travel. [16] [12]

1. Addiction treatment at COGNIFUL — COGNIFUL
2. Life at COGNIFUL in Mallorca — COGNIFUL
3. Drug addiction: getting help — NHS
4. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class — US Food and Drug Administration
5. ASAM/AAAP clinical practice guideline on the management of stimulant use disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry
6. Center for Addiction Disorders, Selnaustrasse — Psychiatric University Hospital Zurich
7. Addiction disorders and dual diagnoses — Psychiatric University Hospital Zurich
8. Opioid use disorder: treating — Centers for Disease Control and Prevention
9. Clinical scope, suitability and care coordination — COGNIFUL
10. Understanding your risk for cannabis use disorder — Centers for Disease Control and Prevention
11. Psychosocial interventions for cannabis dependence — World Health Organization
12. COGNIFUL programs, fees and admissions — COGNIFUL
13. Reintegration and continuing care — COGNIFUL
14. Clinical team and care coordination — COGNIFUL
15. How residential treatment works at COGNIFUL — COGNIFUL
16. Professional referrals — COGNIFUL

Source information checked October 18, 2026. Confirm current services, eligibility, fees, and availability directly with each provider.